This site is intended for healthcare professionals

2437 pages added, reviewed or updated during the last month (last updated: 22/4/2021)

2437 pages added, reviewed or updated during the last month (last updated: 22/4/2021)


Medical search

treatment

FREE subscriptions for doctors and students... click here
You have 3 more open access pages.

Seek expert advice.

Management

  • induction treatment for most patients with ANCA associated vasculitis (AAV) should be with cyclophosphamide or rituximab and glucocorticoids
  • AAV should be considered to be a chronic disease needing longterm immunosuppressive therapy
  • rituximab should be considered as an alternative induction agent for those at high risk of infertility and infection
  • mortality remains high, and late death is due to cardiovascular disease, infection (secondary to treatment) and malignancy

Notes:

  • role of serial ANCA measurement in determining treatment during remission remains controversial
  • some current evidence suggests patients in whom ANCA remains present or rises more than fourfold are at greater risk of relapse.

Reference:

  • Davies DJ. Small vessel vasculitis. Cardiovascular Pathology 2005; 14 (6): 335-346.
  • ARC Autumn 2012. Topical Reviews - ANCA-associated vasculitis; 1:1-12.
  • Yates A, Watts R. ANCA-associated vasculitis. Clinical Medicine 2017 Vol 17, No 1: 60–4

Last edited 05/2020 and last reviewed 05/2020

Links: